Logan Hollis Mackie

Dr. Logan Hollis Mackie

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZAZainab Al-Quraishi
Zainab Al-Quraishi
HAHawraa Ali-Jerman
Hawraa Ali-Jerman
Partha LaskarPartha Laskar
Partha Laskar
AMAshish Arvind Muglikar
Ashish Arvind Muglikar
LMLogan Hollis Mackie
Logan Hollis Mackie
Christine DufèsChristine Dufès
Christine Dufès
Background/Objectives: Prostate cancer is the most commonly diagnosed cancer in men and a leading cause of cancer-related mortality, highlighting the need for delivery systems capable of efficiently transporting both chemotherapeutic drugs and therapeutic genes to tumor cells. Generation-3 diaminobutyric polypropylenimine (DAB) dendrimers display low toxicity, high drug loading capacity and efficient gene delivery, and can be engineered as camptothecin-bearing PEGylated carriers complexed with plasmid DNA. The aim of this study was to compare microfluidic processing with conventional hand mixing for the preparation of camptothecin-bearing PEGylated DAB dendriplexes and to evaluate the impact of formulation methods and microfluidic parameters on their physicochemical properties, cellular uptake and gene expression in prostate cancer cells. Methods: Camptothecin-bearing PEGylated DAB dendrimers were synthesized and complexed with plasmid DNA to form dendriplexes. Formulations were prepared either by microfluidics, using different total flow rates and aqueous: organic flow rate ratios, or by conventional hand mixing. The resulting dendriplexes were characterized for DNA condensation, particle size, polydispersity index and zeta potential. Morphology was assessed by transmission electron microscopy. Cellular uptake of fluorescein-labelled DNA and β-galactosidase reporter gene expression were evaluated in PC3-Luc and DU145 prostate cancer cells. Results: Both microfluidic and hand-mixed methods produced stable, nanosized, positively charged dendriplexes with efficient and sustained DNA condensation (more than 99% over 24 h). Microfluidic processing, particularly at an aqueous: organic flow rate ratio of 3:1, yielded dendriplexes with hydrodynamic diameters and zeta potentials comparable to or slightly improved over hand-mixed formulations. These microfluidic conditions significantly enhanced cellular uptake in both PC3-Luc and DU145 cells. In PC3-Luc cells, this translated into β-galactosidase expression levels comparable to hand-mixed dendriplexes and higher than naked DNA, whereas in DU145 cells, transfection efficiencies remained modest for all formulations despite increased uptake. Conclusions: Microfluidic processing enables the reproducible and scalable preparation of camptothecin-bearing PEGylated DAB dendriplexes with tunable physicochemical properties. Under selected conditions, in vitro cellular uptake and gene expression were comparable to conventional hand mixing, supporting microfluidics as a robust alternative platform for the manufacture of dendrimer-based systems for combined chemo–gene delivery in prostate cancer.

16 May 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
IAIkeoluwa Adekoya
Ikeoluwa Adekoya
MMMichelle Maclean
Michelle Maclean
LMLogan Hollis Mackie
Logan Hollis Mackie
Katharine CarterKatharine Carter
Katharine Carter
Cutaneous leishmaniasis is a protozoan disease which is responsible for significant morbidity in humans. Currently, there is no clinically approved vaccine to prevent infections, and, therefore, treatments to cure skin lesions are required. Ideally, a treatment that can be self-administered to affected areas is desirable. In this study, the effect of violet-blue light, of wavelength in the region of 405 nm, on the survival of Leishmania major and Leishmania mexicana was determined using in vitro and in vivo models. Light treatment caused significant killing of both promastigotes and intracellular amastigotes (p < 0.001) of both species in vitro, and L. mexicana intracellular amastigotes were more resistant to light treatment than L. major intracellular amastigotes. Treatment with violet-blue light at a dose of 45 J/cm2 (0.15 W/cm2 for 5 min) per day on days 3–7 post-infection in an in vivo footpad model caused a significant reduction in L. major parasite burdens on day 5 post-infection (p < 0.05) in one of two experiments, though by day 10 post-infection, parasite numbers had recovered to those of controls. The results of this study clearly demonstrate that violet-blue light can kill both L. major and L. mexicana parasites, but application to infected cutaneous tissues requires refinement.